Journal for Re Attach Therapy and Developmental Diversities
eISSN: 2589-7799
2023 August; 6 (1): 690-696

Advancements in Protein Folding: Implications for Disease Mechanisms

Dr. Sagita R. Patil , Dr. Anup S. Hendre, Dr. Sudarshan N. Shelke , Dr. Mandakini S. Kshirsagar, Dr. Vaishali S. Pawar,
1 Associate , Professor Department of Biochemistry , Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad, Email ID-sangita.patil5@gmail.com
2 Assistant Professor Department of Biochemistry , Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad
3 Associate Professor Department of Biochemistry , Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad
4 Assistant Professor, Department of Biochemistry, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad
5 Assistant Professor, Department of Biochemistry, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad

Received: 24- June -2023
Revised: 27- July -2023
Accepted: 21- August -2023

Abstract

The dynamics of protein folding are essential for both the etiology of disease and cellular function. Comprehending the complex processes that dictate protein folding has revealed its importance in a range of medical ailments, including cancer, metabolic disorders, and neurodegenerative diseases like Parkinson's and Alzheimer's. This review examines the implications of protein folding studies for disease mechanisms by synthesizing current advances in the field. Examining the intricacies of post-translational changes, the cellular milieu, and molecular chaperones, this study underscores the significance of protein misfolding in the advancement of disease. It also covers therapeutic approaches that aim to correct abnormal protein folding, including RNA-based interventions, gene therapies, immunotherapies, and small molecules. Therapeutic methods are a dynamic field that presents promising options for the management of disorders resulting from dysregulation of proteostasis.

Keywords: Protein folding, molecular chaperones, neurodegenerative diseases, metabolic syndromes, cancer.

Introduction

Comprehending the complexities of protein folding has become essential to understanding the molecular causes of many disorders [1]. Because of its significance for both health and sickness, the dynamic and intricate process of protein folding—which is essential for the functional shape of proteins—has attracted more and more attention [2]. Proteins are necessary macromolecules that carry out a wide range of biological processes, such as signaling routes, enzymatic activity, and structural support [3]. Nonetheless, their three-dimensional structure—which mostly depends on appropriate folding mechanisms—is inextricably related to their functionality [4].

A variety of molecular chaperones, folding enzymes, and intracellular environments all play a key role in the tightly controlled sequence of events that constitute protein folding [5]. Recent developments in biophysical methods have yielded previously unheard-of insights into the complex dynamics of protein folding at atomic resolutions, including nuclear magnetic resonance (NMR) spectroscopy and cryo-electron microscopy (cryo-EM) [6]. These methods have made transient folding intermediates visible and characterized, revealing the variety and intricacy of folding routes [7].

Crucially, the importance of comprehending protein folding extends to the field of disease processes and goes beyond basic biology [8]. Misfolding of proteins is a common trait seen in many clinical situations, resulting in the production of abnormal aggregates or amyloid fibrils [9]. Misfolded proteins, such as beta-amyloid, tau, alpha-synuclein, and superoxide dismutase 1 (SOD1), accumulate in neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) [10].

Recent studies have shed insight on the complexities of protein misfolding in relation to neurodegenerative disorders, with a particular focus on the harmful gain-of-function pathways linked to aggregated proteins [11].

For example, synaptic dysfunction and neuronal toxicity in Alzheimer's disease have been linked to the structural alterations and aggregation propensity of beta-amyloid peptides [12]. Similarly, Parkinson's disease-related neuronal cell death and dysfunction have been linked to alpha-synuclein aggregates [13].

Aberrant protein folding has been linked to metabolic syndromes and the etiology of cancer in addition to neurodegenerative diseases [14]. A growing body of research indicates that protein misfolding may play a role in the emergence of insulin resistance in diabetes or altered signaling pathways in obesity [15]. Protein folding defects in cancer affect the growth, metastasis, and responsiveness of tumor cells to treatment [16].

The development of therapeutic approaches has been sparked by a growing interest in comprehending the molecular mechanisms underlying protein misfolding and the implications this has for cellular function [17]. Proteostasis modulators, gene treatments, small compounds, and molecular chaperones are a few of the tactics being investigated to improve the removal of misfolded proteins or restore correct protein folding [18].

Protein Folding Dynamics

The intricate coordination of events known as protein folding dynamics is essential in achieving a functional three-dimensional structure from linear polypeptide chains [1]. The process, which is triggered by environmental stimuli and cellular machinery, starts as soon as translation is completed and involves the nascent polypeptide chain folding into its natural conformation [2].

Our knowledge of the mechanisms controlling protein folding dynamics has greatly increased in recent years, illuminating the complex routes and variables affecting the process [3]. A key component is the function of specialized proteins called molecular chaperones, which help fold and stabilize developing or misfolded proteins [4]. Chaperones such as Hsp70 and Hsp90 promote appropriate folding trajectories and inhibit unproductive interactions, hence aiding in the folding of freshly generated proteins [5].

Furthermore, co-translational folding—the process by which proteins begin folding during translation—has drawn notice as a crucial factor influencing the structure and functionality of proteins [6]. This process entails the translation and folding of proteins simultaneously, and new research indicates how crucial it is for regulating the fidelity and efficiency of protein folding [7].

Post-translational modifications (PTMs) have been identified as an additional crucial factor impacting the dynamics of protein folding [8]. PTMs affect protein stability, shape, and interactions; as a result, they can modify the folding processes [9]. These PTMs include phosphorylation, glycosylation, and ubiquitination. For example, the folding kinetics and stability of proteins have been found to be impacted by conformational changes brought about by phosphorylation in particular sites [10].

Comprehending the energy terrain of protein folding has emerged as a central focus of contemporary research initiatives [11]. The interaction between kinetic traps and energy minima is highlighted by the energy landscape hypothesis, which clarifies the different routes a protein takes during folding [12]. The investigation of these landscapes has been made easier by recent computational techniques, such as sophisticated algorithms and molecular dynamics simulations, which have provided insights on folding intermediates and transition states [13].

Furthermore, a description of the conformational search space during folding has been made possible by the use of the folding funnel idea [14]. Folding funnels illustrate a smooth energy landscape in which proteins use a variety of paths to travel toward their native structure while dodging misfolded conformations and kinetic traps [15]. This idea has given rise to a paradigm for comprehending how proteins effectively reach their native states. The study of protein folding dynamics has been transformed by experimental methods such as cryo-electron microscopy (cryo-EM) and single-molecule fluorescence resonance energy transfer (smFRET) [16]. The imaging and characterisation of transient folding intermediates and conformational changes that occur throughout the folding process are made possible by these approaches, which provide previously unheard-of spatial and temporal resolution [17].

Moreover, it is impossible to overstate the impact that cellular settings, such as the packed cytoplasm or particular organelles, have on the kinetics of protein folding [18]. The thermodynamic stability and folding dynamics of proteins are influenced by macromolecular crowding, which is akin to the physiological circumstances found in cells [19]. Protein folding and quality control processes are significantly impacted by unique folding machinery

and redox conditions found in organelle-specific settings, such as the endoplasmic reticulum (ER) or mitochondria [20].

Implications in Neurodegenerative Diseases

Because protein misfolding plays a major role in the etiology of these crippling disorders, the implications of misfolding in neurodegenerative illnesses have attracted a lot of attention [1]. Neurodegenerative diseases are a group of conditions that are typified by a progressive loss of function and degeneration of the neurons. These diseases include amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD) [2].

The pathological characteristic of Alzheimer's disease is the formation of tau tangles and beta-amyloid (Aβ) plaques [3]. Amyloid precursor protein (APP) is the source of Aβ, which is processed abnormally and causes insoluble aggregates and plaques in the brain [4]. These clumps impair synaptic function and set off neurotoxic cascades, which exacerbate neuronal death and cognitive impairment [5].

Furthermore, in AD, neuronal dysfunction and cognitive impairment are correlated with tau protein misfolding and aggregation into neurofibrillary tangles (NFTs) [6]. Tau is a microtubule-associated protein that is essential for maintaining the stability of the neuronal cytoskeleton. It can become misfolded and produce harmful fibrils and oligomers, which can hinder synaptic function and axonal transit [7].

Similar to this, one degenerative feature of Parkinson's disease is the aggregation of alpha-synuclein (α-syn) into Lewy bodies within neurons [8]. Disruptions to cellular homeostasis caused by α-syn aggregates result in inefficient protein clearance processes, dysfunctional mitochondria, and eventually neuronal degeneration [9]. One factor contributing to Parkinson's disease's degenerative character is the dispersion of α-syn aggregates throughout linked brain areas [10].

Motor neurons selectively degenerate in amyotrophic lateral sclerosis (ALS), another devastating neurodegenerative disease [11]. The pathophysiology of ALS is linked to protein misfolding; mutations in SOD1 and other proteins cause these proteins to misfold and aggregate, which in turn increases the toxicity to motor neurons [12].

Determining the mechanisms behind protein misfolding and aggregation in neurodegenerative disorders has been the focus of recent study [13]. The hazardous gain-of-function characteristics of misfolded proteins, which disturb cellular homeostasis and cause neurotoxicity, have been exposed by studies into the structural dynamics of these proteins [14].

Furthermore, misfolded protein propagation—also known as "prion-like" propagation—across neural networks has drawn interest in neurodegenerative illnesses [15]. This phenomena entails the prion-like spread of disease pathology and illness development by the transmission of misfolded protein conformations from one cell to another [16].

Moreover, a great deal of research has been done on the function of protein quality control systems, such as the autophagy-lysosomal pathways and the ubiquitin-proteasome system, in reducing the effects of misfolding of proteins [17]. Protein aggregation is made worse by malfunctioning protein clearance pathways, which ultimately results in cellular toxicity and neuronal death [18].

Research on therapeutic approaches that target misfolding of proteins in neurodegenerative disorders is very active [19]. Strategies include gene treatments that alter protein expression or folding pathways, immunotherapies that target misfolded proteins, and small molecule inhibitors that block protein aggregation [20].

Metabolic Syndromes and Protein Misfolding

Recent data points to an intriguing interaction between protein misfolding and the onset or course of metabolic syndromes, which include diseases including obesity, diabetes, and metabolic dysregulation [1]. Complex conditions known as metabolic syndromes are typified by a number of interrelated risk factors that raise the risk of cardiovascular disease and type 2 diabetes. These risk factors include insulin resistance, dyslipidemia, hypertension, and abdominal obesity [2].

The influence of protein homeostasis or proteostasis on cellular metabolism is the source of the link between protein misfolding and metabolic disorders [3]. Metabolic dysregulation has been linked to disruptions in proteostasis, which include abnormalities in protein folding, breakdown, or clearance pathways [4].

A characteristic of type 2 diabetes and the metabolic syndrome, insulin resistance has been linked to malfunctioning protein folding mechanisms [5]. The unfolded protein response (UPR), an adaptive cellular mechanism intended to restore protein homeostasis, is triggered by the buildup of misfolded proteins within the endoplasmic reticulum (ER) [6]. Insulin signaling pathways are hampered and inflammatory responses are encouraged by prolonged ER stress and UPR activation, which both lead to insulin resistance [7].

Furthermore, certain proteins implicated in glucose metabolism and insulin signaling are prone to misfolding, which can affect cellular processes [8]. For example, disruption of insulin sensitivity and glucose uptake has been linked to misfolded versions of insulin receptor substrates (IRS) or glucose transporters (GLUT) [9].

Protein folding pathway disruptions have also been connected to obesity, a significant aspect of the metabolic syndrome [10]. Obesity-related adipose tissue dysfunction raises the synthesis of adipokines and pro-inflammatory cytokines, which in turn causes ER stress, altered proteostasis, and chronic low-grade inflammation [11]. Metabolic dysfunction and insulin resistance may be made worse by this dysregulated proteostasis [12].

Moreover, it has been suggested that changes in the makeup of the gut microbiota, which are linked to metabolic syndrome and obesity, encourage protein misfolding and metabolic dysregulation [13]. The production of metabolites or bacterial components by dysbiotic microbiota can cause ER stress, which can affect host proteostasis and set off inflammatory reactions [14].

There has been interest in the function of particular molecular chaperones and protein quality control systems in metabolic disorders [15]. Heat shock proteins (Hsps), for example, are chaperones that are essential for preserving the integrity of protein folding and avoiding the build-up of misfolded proteins [16]. Protein aggregation and metabolic disorders are caused in part by malfunctioning chaperone mechanisms or compromised proteasomal degradation pathways [17].

Furthermore, altered protein folding and stability have been linked to certain genetic abnormalities connected to metabolic disorders [18]. Misfolded protein synthesis can result from variations in genes related to adipocyte function, insulin signaling, or lipid metabolism [19]. This can exacerbate metabolic dysregulation.

Cancer and Aberrant Protein Folding

Because of its effect on tumor start, development, and treatment responses, the significance of abnormal protein folding in cancer pathogenesis has attracted a lot of attention [1]. Uncontrolled cell proliferation, apoptosis evasion, and metastatic spread are characteristics of cancer. New research indicates that dysregulated protein folding processes are critical to these characteristics [2].

Numerous malignancies have been linked to protein misfolding and aggregation, which can affect tumor cell invasion, proliferation, and treatment resistance [3]. Tumorigenesis and malignant transformation are facilitated by changes in the folding patterns of certain proteins that are involved in cell signaling, cell cycle regulation, and DNA repair mechanisms [4].

In cancer cells, chaperone proteins—which are necessary for preserving protein homeostasis—often show dysregulated expression or function [5]. Heat shock proteins (Hsps), like as Hsp90 and Hsp70, are important folding and stabilizing proteins that fold oncoproteins, promoting tumor growth and survival. They are often overexpressed in cancer [6].

Moreover, appropriate protein folding and quality control systems are challenged by the hypoxic, nutrient-deficient, and acidic circumstances of the tumor microenvironment [7]. These circumstances have the ability to cause ER stress and trigger the unfolded protein response (UPR) in cancer cells, which encourages survival and adaptability mechanisms that accelerate the growth of tumors [8].

Certain tumor suppressors and oncoproteins are prone to misfolding, which can change how they function and affect the way cancer cells behave [9]. Tumor suppressor proteins, like p53, are susceptible to misfolding and loss of function due to mutations, which impairs their capacity to control DNA repair and cell cycle progression [10].

Additionally, aberrant signaling cascades that support cell survival and proliferation are facilitated by misfolded oncoproteins such as mutant transcription factors or kinases [11].
Additionally, post-translational modifications (PTMs) affect cellular signaling pathways by influencing the folding and stability of proteins in cancer cells [12]. Protein shape and interactions can be changed by dysregulated PTMs, such as phosphorylation, acetylation, or glycosylation, which can promote oncogenic signaling and tumor growth [13].

The idea of proteotoxic stress in cancer draws attention to the fine balance that exists between the ability of proteins to fold and the needs of cells [14]. higher rates of protein synthesis, mutations in parts of the folding machinery, or changes in the pathways leading to protein degradation all cause cancer cells to be under higher proteotoxic stress [15]. In addition to impairing cellular functioning and increasing medication resistance, this stress can also encourage protein aggregation [16].

Current cancer treatment approaches that target abnormal protein folding try to take advantage of weaknesses brought on by deregulation of the proteostatic system [17]. Preclinical studies have demonstrated the potential of small molecule inhibitors that specifically target cancer cells and induce proteotoxic stress by targeting chaperones or proteasomal degradation pathways [18]. Furthermore, methods that alter proteostasis regulators or protein folding pathways are being investigated as possible anticancer tactics [19].

Therapeutic Approaches Targeting Protein Misfolding

Treatment approaches that try to lessen the effects of misfolded proteins have become attractive options for treating a range of illnesses associated with dysregulation of proteostasis, such as cancer, metabolic syndromes, neurodegenerative diseases, and different protein misfolding diseases [1]. These tactics mostly concentrate on improving protein clearance, getting at the misfolded proteins directly, or restoring correct protein folding [2].

Tiny compounds that target protein misfolding have drawn interest as possible treatments for a variety of disease scenarios [3]. By stabilizing intermediates, preventing abnormal aggregation, or modifying protein shape, these compounds lessen the harmful effects of misfolded proteins [4]. For example, preclinical studies have demonstrated promise in neurodegenerative disorders such as Alzheimer's and Parkinson's due to the action of small molecules targeting amyloid beta or alpha-synuclein aggregation, which reduces the buildup of harmful aggregates [5].

Molecular chaperones have also been investigated as potential therapeutic targets because they are essential for promoting appropriate protein folding and averting aggregation [6]. Chemical chaperones, sometimes referred to as pharmacological chaperones, are small compounds that improve chaperone function by stabilizing folded conformations or assisting in proper protein folding [7]. These compounds have demonstrated promise in lessening the effects of misfolded proteins linked to lysosomal storage diseases, including Fabry disease and Gaucher's disease [8].

Furthermore, a possible therapeutic strategy is to improve the cellular machinery in charge of protein quality control and clearance [9]. Approaches to increase autophagy have been studied [10]. Autophagy is the cellular mechanism that breaks down misfolded proteins and aggregates. on neurodegenerative disorders, inducing autophagy with pharmacological drugs or dietary interventions has demonstrated positive effects on the clearance of protein aggregates [11].

The goal of gene treatments for protein misfolding disorders is to enhance the protein folding machinery or fix underlying genetic mutations [12]. The goal of strategies utilizing gene editing, RNA interference, or gene supplementation is to improve the removal of misfolded proteins or restore appropriate protein folding [13].

These tactics may be useful for hereditary protein misfolding illnesses such as some types of familial amyloidosis and cystic fibrosis [14].

Moreover, immunotherapies targeting misfolded proteins have become popular in the fight against illnesses caused by misfolding of proteins [15]. Targeting certain misfolded protein epitopes, antibodies or vaccine-based strategies seek to improve clearance processes or counteract the harmful consequences of aggregates [16]. Clinical studies for immunotherapies have begun after they demonstrated promise in preclinical models of neurodegenerative disorders [17].

or control gene expression linked to protein misfolding disorders are provided by emerging technologies, such as RNA-based therapies [18]. Antisense oligonucleotides and RNA interference are examples of RNA-targeting tactics that may be able to rectify faulty RNA processing in disorders such as amyotrophic lateral sclerosis (ALS) or decrease the creation of misfolded proteins [19].

To improve efficacy and address the complexity of proteostasis dysregulation, combination treatments that target different parts of protein misfolding pathways or that employ synergistic techniques are being investigated [20]. These strategies aim to produce synergistic effects on protein folding, clearance, or cellular responses by combining small compounds with gene treatments, immunotherapies, or RNA-based interventions.

Conclusion

To conclude, protein folding dynamics and its effects on various diseases have illuminated the intricate molecular mechanisms that regulate cell health and function. Protein misfolding is linked to cancer, metabolic disorders, and neurological diseases including Parkinson's and Alzheimer's. This review covers the latest protein folding research and its effects on a variety of medical conditions.

Interactions between molecular chaperones, co-translational folding, post-translational modifications, and the cellular environment make protein folding dynamics complex. Biophysical techniques like single-molecule fluorescence resonance energy transfer and cryo-electron imaging have improved our understanding of protein structural changes and transitory folding intermediates.

Research has focused on neurodegenerative diseases caused by tau, alpha-synuclein, and beta-amyloid misfolding. Understanding the detrimental gain-of-function mechanisms of these aggregates may reveal therapeutic targets. Similarly, protein misfolding and metabolic illnesses like diabetes and obesity explain the association between cellular proteostasis and systemic health.

Protein folding abnormalities contribute to cancer's complicated signaling networks and unregulated cell growth. Targeting misfolded oncoproteins and manipulating cancer cell proteostasis are promising therapeutic approaches.

Gene therapies that correct genetic defects and small molecules that target misfolded proteins are utilized to cure protein misfolding. Immunotherapies, RNA-based interventions, and combination therapies show the variety of cutting-edge protein misfolding disorder treatments.

References

1. Valastyan, J. S., & Lindquist, S. (2014). Mechanisms of protein-folding diseases at a glance. *Disease models & mechanisms*, *7*(1), 9–14. https://doi.org/10.1242/dmm.013474
2. Hendrick, J. P., & Hartl, F. U. (1995). The role of molecular chaperones in protein folding. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, *9*(15), 1559–1569. https://doi.org/10.1096/fasebj.9.15.8529835
3. Ramazi, S., & Zahiri, J. (2021). Posttranslational modifications in proteins: resources, tools and prediction methods. *Database : the journal of biological databases and curation*, *2021*, baab012. https://doi.org/10.1093/database/baab012
4. Yadav, K., Yadav, A., Vashistha, P., Pandey, V. P., & Dwivedi, U. N. (2019). Protein Misfolding Diseases and Therapeutic Approaches. *Current protein & peptide science*, *20*(12), 1226–1245. https://doi.org/10.2174/1389203720666190610092840
5. Strub, M. D., & McCray, P. B., Jr (2020). Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease. *Genes*, *11*(5), 546. https://doi.org/10.3390/genes11050546
6. Pampalone, G., Grottelli, S., Gatticchi, L., Lombardi, E. M., Bellezza, I., & Cellini, B. (2021). Role of misfolding in rare enzymatic deficits and use of pharmacological chaperones as therapeutic approach. *Frontiers in bioscience (Landmark edition)*, *26*(12), 1627–1642. https://doi.org/10.52586/5056
7. Hervás, R., & Oroz, J. (2020). Mechanistic Insights into the Role of Molecular Chaperones in Protein Misfolding Diseases: From Molecular Recognition to Amyloid Disassembly. *International journal of molecular sciences*, *21*(23), 9186. https://doi.org/10.3390/ijms21239186

8. Gandhi, J., Antonelli, A. C., Afridi, A., Vatsia, S., Joshi, G., Romanov, V., Murray, I. V. J., & Khan, S. A. (2019). Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics. *Reviews in the neurosciences*, *30*(4), 339–358. https://doi.org/10.1515/revneuro-2016-0035
9. Karatas, E., & Bouchecareilh, M. (2020). Alpha 1-Antitrypsin Deficiency: A Disorder of Proteostasis-Mediated Protein Folding and Trafficking Pathways. *International journal of molecular sciences*, *21*(4), 1493. https://doi.org/10.3390/ijms21041493
10. Estabrooks, S., & Brodsky, J. L. (2020). Regulation of CFTR Biogenesis by the Proteostatic Network and Pharmacological Modulators. *International journal of molecular sciences*, *21*(2), 452. https://doi.org/10.3390/ijms21020452
11. Coyne, L. P., & Chen, X. J. (2019). Consequences of inner mitochondrial membrane protein misfolding. *Mitochondrion*, *49*, 46–55. https://doi.org/10.1016/j.mito.2019.06.001
12. Needham, P. G., Guerriero, C. J., & Brodsky, J. L. (2019). Chaperoning Endoplasmic Reticulum-Associated Degradation (ERAD) and Protein Conformational Diseases. *Cold Spring Harbor perspectives in biology*, *11*(8), a033928. https://doi.org/10.1101/cshperspect.a033928
13. Caballero, A. B., & Gamez, P. (2021). Nanochaperone-Based Strategies to Control Protein Aggregation Linked to Conformational Diseases. *Angewandte Chemie (International ed. in English)*, *60*(1), 41–52. https://doi.org/10.1002/anie.202007924
14. Suzuki Y. (2023). Chaperone therapy for lysosomal and non-lysosomal protein misfolding diseases. *Brain & development*, *45*(5), 251–259. https://doi.org/10.1016/j.braindev.2023.02.004
15. Grasso, D., Galderisi, S., Santucci, A., & Bernini, A. (2023). Pharmacological Chaperones and Protein Conformational Diseases: Approaches of Computational Structural Biology. *International journal of molecular sciences*, *24*(6), 5819. https://doi.org/10.3390/ijms24065819
16. Shin, M. H., & Lim, H. S. (2017). Screening methods for identifying pharmacological chaperones. *Molecular bioSystems*, *13*(4), 638–647. https://doi.org/10.1039/c6mb00866f
17. Hekmatimoghaddam, S., Zare-Khormizi, M. R., & Pourrajab, F. (2017). Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases. *BioFactors (Oxford, England)*, *43*(6), 737–759. https://doi.org/10.1002/biof.1264
18. Hou, Z. S., Ulloa-Aguirre, A., & Tao, Y. X. (2018). Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders. *Expert review of clinical pharmacology*, *11*(6), 611–624. https://doi.org/10.1080/17512433.2018.1480367
19. Tao, Y. X., & Conn, P. M. (2018). Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases. *Physiological reviews*, *98*(2), 697–725. https://doi.org/10.1152/physrev.00029.2016
20. Sontag, E. M., Samant, R. S., & Frydman, J. (2017). Mechanisms and Functions of Spatial Protein Quality Control. *Annual review of biochemistry*, *86*, 97–122. https://doi.org/10.1146/annurev-biochem-060815-014616